Supplementary Materials Supplemental Data supp_28_9_2777__index. in MSC-treated subjects (from 12.1% [3.3,

Supplementary Materials Supplemental Data supp_28_9_2777__index. in MSC-treated subjects (from 12.1% [3.3, 17.8] to 6.8% [1.8, 12.9]; tended Dinaciclib price to decrease in both kidneys after MSC treatment but did not reach statistical significance. Open in a separate window Number 4. Renal vein levels of VEGF-C decreased after MSC treatment. Renal vein levels of VEGF-C decreased 3 months after MSC treatment both in the STK and CLK (checks with unequal variance (or the Wilcoxon rank-sum test for skewed data) for continuous variables, and a chi-squared test or Fisher precise test for categoric variables as appropriate. Comparisons between two kidneys within Dinaciclib price the same individuals and repeated measurements for specific kidneys within individuals before and after treatment were performed using combined checks. Percent (%) switch in STK-GFR was determined as: ([(3 months STK-GFR?baseline STK-GFR)/baseline STK-GFR] 100%). Statistical significance was approved for em P /em 0.05. Statistical analysis was performed using JMP software package version 8.0 (SAS Institute Inc., Cary, NC). Total and detailed methods are provided as Supplemental Material. Disclosures None. Supplementary Material Supplemental Data: Click here to view. Acknowledgments The authors would like to Dinaciclib price say thanks to Beverly Tietje, for her part as study coordinator throughout the period of this study. We also thank Darcie Radel, Greg Butler, Pranathi Madde, Kathy Allen, Kathleen Soiney, and Karin Zachau for product manufacture. The Human being Cell Therapy Lab receives support from your Division of Laboratory Medicine and Pathology, the Center for Translational Study, and the Center Dinaciclib price of Regenerative Medicine. Furthermore, we value the nice philanthropic support of William and Karen Eby, as well as Pdgfra the charitable basis in their titles. This project was partly supported by National Institutes of Health (NIH) grants, including P01 HL85307 from your National Heart, Lung and Blood Institute (NHLBI); R01 DK100081, DK102325, K23 DK109134 and R01 DK73608 from your National Institute of Digestive, Diabetic and Kidney Diseases (NIDDK); as well as Clinical and Translational Technology Dinaciclib price Award Give UL1 RR024150 from NIH/The National Center for Study Resources. Our studies were also supported by funds from the Center of Regenerative Medicine at Mayo Medical center. The content is definitely solely the responsibility of the authors and does not represent the official views of the NHLBI, NIDDK, or NIH. Footnotes Published online ahead of print. Publication day available at www.jasn.org. This short article contains supplemental material on-line at http://jasn.asnjournals.org/lookup/suppl/doi:10.1681/ASN.2017020151/-/DCSupplemental..